NL-OMON50913已完成不适用
2000HIV Trained Innate Immunity in HIV elite controllers - 2000HIV-Trained
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 120
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Observational
入排标准
- 年龄范围
- 18 至 99（—）
入选标准
- •All participants/first degree relatives:
- •1. All participants must be *18 years of age.
- •HIV elite controllers:
- •1. Participation in 2000HIV study
- •2. Available first-degree relative
- •3. Meet criteria of elite controller (see protocol page 7 for elaborate
- •definition)
- •ART-suppressed people with HIV:
- •1. On cART *6 months with an HIV-RNA load <200 copies/mL
- •2. Never applied to controller definition.
- •3. At least one documented HIV RNA load >100.000 copies/mL
- •4. No documentation of recent HIV acquisition combined with ART initiation in
- •less than 6 months
- •5. Available first-degree relative
排除标准
- •All participants:
- •1. Active hepatitis B/C or signs of acute infections
- •2. Active or recent malignant condition (i.e. <12 months ago treated)
- •3. Active systemic auto-immune or auto-inflammatory conditions (such as
- •rheumatoid arthritis, inflammatory bowel disease).
- •4. Use of immunosuppressive medication
- •5. Pregnant
研究者
相似试验
已完成
不适用
2000HIV Trained Innate Immunity in HIV Elite ControllersHIV-1-infectionNCT04968717Radboud University Medical Center109
招募中
不适用
Immune improvement by antiretroviral therapy in HIV-1 infected childreHuman immunodeficiency virus type 1 (HIV-1) infectionJPRN-UMIN000014809Graduate school of Medicine, Kanazawa University100
已完成
1 期
Therapeutic Vaccine for HIVHIVTherapeutic VaccineNCT01859325National Institute of Allergy and Infectious Diseases (NIAID)33
进行中（未招募）
不适用
Active immunotherapy against HIV during highly active anti-retroviral therapy followed by repeated treatment interruptions, VAC 09. - Vac 09Treatment of HIV infectionEUCTR2005-002849-40-SESwedish Institute for Infectious Disease Control30
招募中
1 期
Virological and immunological assessment in HIV positive participants on 2DR versus 3DR in a prospective randomized controlled switch trial.EUCTR2020-000685-42-BEGhent University Hospital134